These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 31236364)

  • 1. The efficacy and safety of besifloxacin for acute bacterial conjunctivitis: a Meta-analysis.
    Wang JJ; Gao XY; Li HZ; Du SS
    Int J Ophthalmol; 2019; 12(6):1027-1036. PubMed ID: 31236364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating with besifloxacin for acute bacterial conjunctivitis: a Meta-analysis.
    Wang JJ; Gao XY; Li HZ; Du SS
    Int J Ophthalmol; 2019; 12(12):1898-1907. PubMed ID: 31850176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
    McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
    Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
    Comstock TL; Paterno MR; Usner DW; Pichichero ME
    Paediatr Drugs; 2010 Apr; 12(2):105-12. PubMed ID: 20218747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
    Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
    Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of besifloxacin in the treatment of bacterial conjunctivitis.
    Mahvan TD; Hornecker JR; Buckley WA; Clark S
    Ann Pharmacother; 2014 May; 48(5):616-25. PubMed ID: 24566460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.
    DeLeon J; Silverstein BE; Allaire C; Gearinger LS; Bateman KM; Morris TW; Comstock TL
    Clin Drug Investig; 2012 May; 32(5):303-17. PubMed ID: 22420526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates.
    Sanfilippo CM; Allaire CM; DeCory HH
    Drugs R D; 2017 Mar; 17(1):167-175. PubMed ID: 28078599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Antibacterial Efficacy and Safety of Besifloxacin Ophthalmic Suspension Compared With Moxifloxacin Ophthalmic Solution.
    Garg P; Mathur U; Sony P; Tandon R; Morris TW; Comstock TL
    Asia Pac J Ophthalmol (Phila); 2015; 4(3):140-5. PubMed ID: 26065499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
    Chang MH; Fung HB
    Clin Ther; 2010 Mar; 32(3):454-71. PubMed ID: 20399984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
    Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL
    Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies.
    Comstock TL; Paterno MR; Decory HH; Usner DW
    Clin Drug Investig; 2010; 30(10):675-85. PubMed ID: 20629472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections.
    Silverstein BE; Morris TW; Gearinger LS; Decory HH; Comstock TL
    Clin Ophthalmol; 2012; 6():1987-96. PubMed ID: 23233796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis.
    Tepedino ME; Heller WH; Usner DW; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL
    Curr Med Res Opin; 2009 May; 25(5):1159-69. PubMed ID: 19323612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes.
    Morris TW; Gearinger LS; Usner DW; Paterno MR; Decory HH; Comstock TL; Haas W
    Clin Ophthalmol; 2011; 5():1359-67. PubMed ID: 22034555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections.
    Mah FS; Sanfilippo CM
    Ophthalmol Ther; 2016 Jun; 5(1):1-20. PubMed ID: 27010720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis.
    O'Brien TP
    Adv Ther; 2012 Jun; 29(6):473-90. PubMed ID: 22729919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.
    Bertino JS; Zhang JZ
    Expert Opin Pharmacother; 2009 Oct; 10(15):2545-54. PubMed ID: 19743941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
    Proksch JW; Ward KW
    J Ocul Pharmacol Ther; 2010 Oct; 26(5):449-58. PubMed ID: 20874668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial.
    Baiza-Durán L; Olvera-Montaño O; Mercado-Sesma AR; Oregon-Miranda AA; Lizárraga-Corona A; Ochoa-Tabares JC; Pérez-Balbuena AL; Montoya-Sánchez IM; Saucedo-Rodríguez LR; Mora-González A; Gómez-Bastar PA; Villanueva-Najera MA; Sandoval-Delgadillo LI; González-Lomelí M; Páez-Garza JH; Orozco-Carroll M; Casillas-Magallanes M
    J Ocul Pharmacol Ther; 2018 Apr; 34(3):250-255. PubMed ID: 29624493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.